Cell therapy company Cartherics has announced the appointment of Professor Bryan Williams as its new board chair and Laurence Nore as a non-executive director.
Professor Williams has been a non-executive Director of Cartherics since 2017. He is an internationally recognised cancer researcher with considerable board experience in both private and listed companies as well as research institutes and associations.
“I am very pleased to step up to Chair the Cartherics Board after serving as a Board member for the past several years. Cartherics has developed a strong patent portfolio, preclinical data and manufacturing processes developing allogeneic CAR-T and CAR-NK cells for treating ovarian cancer and endometriosis. I look forward to working with the Board and management as we move into the clinical phase of our development.,” said Professor Williams.
Professor Williams succeeds Bob Moses, Cartherics founding Chair, who has stepped down for personal reasons.
Laurence Nore is a seasoned business executive with over two decades of experience in the US Life Sciences industry, specialising in therapeutics and diagnostics. Her expertise spans business strategy, mergers and acquisitions, financial management, and partnership structuring.
Ms Nore said, “I’m thrilled to be joining the Board of Cartherics, and I look forward to working with the other Directors and the management team to take the company to the next level and bring hope to patients with cancer, endometriosis and other devastating diseases globally.”
Cartherics CEO Professor Alan Trounson AO said, “Bryan Williams is an international scientific expert in human cancer with strong ties to US institutions and Australasian biotechnology companies. His guidance as Board Chairman in the highly technical field of cancer therapies will be critical for the company’s success. The appointment of Laurence Nore as Non-Executive Director is especially important because of her European and American business experience in the field of medical biotechnology and will considerably strengthen the company’s potential to navigate the rapidly changing business, financial and regulatory challenges for delivering therapies for cancer and endometriosis.”